January 08, 2025 04:24 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Sheesh Mahal row: AAP leaders who were denied entry into CM's residence turn towards PM's house | Anna University sexual assault accused is a DMK supporter, not member: MK Stalin | Ajit Doval, Raja Dato discuss bilateral cooperation during India-Malaysia Security Dialogue | US President-elect Donald Trump threatens to use economic force to make Canada 51st US State, Justin Trudeau retorts sharply | Elon Musk raises concern on 'world population decline' including that of India, China | Indian-origin Anita Ananda might replace Justin Trudeau as Canadian PM | 'I won't bite': Kamala Harris tells Senator's husband as he refuses to shake hands with her | Centre announces memorial for Pranab Mukherjee, his daughter thanks PM Modi for 'gracious gesture' | Delhi assembly elections on Feb 5, results on Feb 8 | Allu Arjun visits boy injured during Pushpa 2 stampede in Hyderabad

Pfizer COVID-19 antiviral pill shows it cuts risks of hospitalization, death by 89 percent

Nov 05, 2021, at 11:30 pm

Pharmaceutical giant Pfizer Inc on Friday announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness.